73 Results

People

  1. Usmani
    Usmani
  2. Landgren
    Landgren
  3. Mailankody
    Mailankody
  4. Giralt
    Giralt
  5. Lesokhin
    Lesokhin
  6. Korde
    Korde
  7. Shah
    Shah
  8. Hassoun
    Hassoun
  9. Landau
    Landau
  10. Hultcrantz
    Hultcrantz

Groups

  1. Department of Medicine (54)
  2. Hematologic Malignancies, Division of (49)
  3. Center for Hematologic Malignancies (44)
  4. Myeloma (31)
  5. Hematologic Malignancies Research (24)
  6. Survivorship Research (20)
  7. Bone Marrow Transplant (17)
  8. CTCR Scholars (12)
  9. Graduate Medical Education (12)
  10. GME, Medicine (11)
  1. "carfilzomib"
Formats
  1. Journal Article (53)
  2. Review (11)
  3. Research Letter (4)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Correspondence (1)
  7. Meeting Abstract (1)
Groups
  1. Department of Medicine (54)
  2. Hematologic Malignancies, Division of (49)
  3. Center for Hematologic Malignancies (44)
  4. Myeloma (31)
  5. Hematologic Malignancies Research (24)
  6. Survivorship Research (20)

More Groups

People
  1. Saad Usmani (16)
  2. Carl Landgren (14)
  3. Sham Mailankody (14)
  4. Alexander Lesokhin (13)
  5. Sergio Giralt (13)
  6. Neha Korde (12)

More People

Years
  1. 2025 (5)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (8)
  5. 2021 (5)
  6. 2020 (5)

More Years

Publications
  1. American Journal of Hematology (5)
  2. Blood (5)
  3. Clinical Lymphoma, Myeloma and Leukemia (4)
  4. Blood Advances (3)
  5. Blood Cancer Journal (3)
  6. Best Practice and Research: Clinical Haematology (2)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. American Society of Hematology (8)
  3. Nature Publishing Group (8)
  4. John Wiley & Sons (6)
  5. John Wiley & Sons, Inc. (5)
  6. Elsevier Science, Inc. (4)

More Publishers

Results (73)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cross fire: Daratumumab-based therapies are standard of care in newly diagnosed multiple myeloma
    Review

    Korde, N.; Usmani, S. Z.
    Hematology-Oncology and Stem Cell Therapy (2023)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens
    Journal Article

    Maura, F.; Boyle, E. M.; Coffey, D.; Maclachlan, K.; Gagler, D.; Diamond, B.; Ghamlouch, H.; Blaney, P.; Ziccheddu, B.; Cirrincione, A.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Polyclonal immunoglobulin recovery in patients with newly diagnosed myeloma receiving maintenance therapy after autologous haematopoietic stem cell transplantation with either carfilzomib, lenalidomide and dexamethasone or lenalidomide alone: Subanalysis of the randomized phase 3 ATLAS trial
    Journal Article

    Kubicki, T.; Dytfeld, D.; Wróbel, T.; Jamroziak, K.; Robak, P.; Czyż, J.; Tyczyńska, A.; Druzd-Sitek, A.; Giannopoulos, K.; Szczepaniak, T.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma
    Journal Article

    Coffey, D. G.; Maura, F.; Gonzalez-Kozlova, E.; Diaz-Mejia, J. J.; Luo, P.; Zhang, Y.; Xu, Y.; Warren, E. H.; Dawson, T.; Lee, B.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: A CIBMTR analysis
    Journal Article

    Ragon, B. K.; Shah, M. V.; D’Souza, A.; Estrada-Merly, N.; Gowda, L.; George, G.; de Lima, M.; Hashmi, S.; Kharfan-Dabaja, M. A.; Majhail, N. S.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Chemoenzymatic synthesis of novel cytotoxic epoxyketones using the eponemycin biosynthetic enzyme EpnF
    Journal Article

    Corless, B. C.; Geißen, R.; Prescott, N. A.; David, Y.; Scheinberg, D. A.; Tan, D. S.
    ACS Chemical Biology (2023)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Stem cell mobilization yields with daratumumab- and lenalidomide-containing quadruplet induction therapy in newly diagnosed multiple myeloma: Findings from the MASTER and GRIFFIN trials
    Journal Article

    Chhabra, S.; Callander, N.; Watts, N. L.; Costa, L. J.; Thapa, B.; Kaufman, J. L.; Laubach, J.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save